Marco Blanco
Principal Scientist Merck & Co
Seminars
Thursday 19th November 2026
Panel Discussion: What Should Be Characterized at Drug Substance vs Drug Product Stage?
12:10 pm
- Explore which attributes should be controlled before formulation versus reassessed in the final LNP product
- Debate how much characterization is enough at different stages of development without creating unnecessary analytical burden
- Benchmark industry approaches for defining CQAs, release strategies, and regulatory-ready analytical packages
Wednesday 18th November 2026
Advancing Structural & Analytical Understanding of Lipid Nanoparticles: From SAXS Method Development to Cross-Functional Standardization
1:30 pm
- Applying SAXS and complementary techniques for LNP structural elucidation and conformational assessment
- Challenges in interpreting ensemble-averaged data in heterogeneous nanoparticle systems
- Progress toward developing standardized analytical frameworks for LNP characterization
